Kopran Ltd

Kopran Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 02 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 June 2026, providing investors with the latest insights into the company’s performance and outlook.

At Rs 187.00, sellers were still queuing — but there were no buyers willing to take the other side. Kopran Ltd locked at its lower circuit of 5% on 3 Jun 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock with limited liquidity.

Kopran Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy, reflecting a notable improvement in its technical indicators, financial results, valuation metrics, and overall quality assessment. This upgrade, effective from 2 June 2026, is underpinned by a combination of stronger quarterly earnings, enhanced technical trends, and attractive valuation compared to peers, signalling renewed investor confidence in the stock.

Kopran Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, upgrading its MarketsMOJO grade from Hold to Buy as of 2 June 2026. This change reflects improving price action and bullish signals across key technical indicators, positioning the stock favourably despite a modest day decline of 0.48% to ₹195.10.

At Rs 186.17, sellers were still queuing — but there were no buyers willing to take the other side. Kopran Ltd locked at its lower circuit of 5.0% on 2 Jun 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock with limited liquidity.

The 50-day moving average has crossed above the 200-day moving average for Kopran Ltd, signalling a golden cross on 1 Jun 2026. Yet, the stock fell 4.99% on the day the cross formed, while monthly technical indicators remain only mildly bullish or neutral. This divergence between the moving averages and other signals calls for a closer examination of the cross’s reliability.

At Rs 195.96, sellers were still queuing — but there were no buyers willing to take the other side. Kopran Ltd locked at its lower circuit of 5.0% on 1 Jun 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock.

Kopran Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 19 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 31 May 2026, providing investors with the latest insights into its performance and outlook.

Surging past its previous peaks, Kopran Ltd touched a new 52-week high of Rs 214.3 on 29 Jun 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and a year-to-date return of 15.22%, comfortably outperforming the Sensex’s decline of 7.33% over the same period.

Kopran Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum following a robust price surge of 15.56% in a single trading session. This change has prompted an upgrade in its MarketsMOJO rating from Sell to Hold, reflecting improved investor sentiment and a cautiously optimistic outlook on the stock’s near-term trajectory.

At Rs 195.81, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Kopran Ltd locked at its upper circuit of 20% on 25 May 2026, with buyers queuing and no sellers willing to part with shares.

Kopran Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a recent downgrade in daily moving averages to mildly bearish, weekly and monthly technical indicators present a complex picture, reflecting mixed signals that investors should carefully analyse before making decisions.

Kopran Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Recent technical indicators, including MACD, Bollinger Bands, and KST, suggest improving price momentum despite some mixed signals from moving averages and monthly trends. This nuanced technical picture offers investors a balanced view of Kopran’s near-term prospects amid broader market challenges.

Kopran Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a recent downgrade in daily moving averages and a 2.93% decline in the stock price, several weekly and monthly technical indicators present a complex picture of the stock’s near-term prospects.

Kopran Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 19 May 2026. This change reflects a marked improvement across financial performance, technical indicators, and valuation metrics, signalling a cautious but positive outlook for investors after a challenging period.